Core Viewpoint - The company reported record-high revenue of HKD 6.11 billion for the first half of 2025, with innovative and barrier products accounting for approximately 51% of total revenue, reflecting a nearly 15 percentage point increase year-on-year [1] Group 1: Financial Performance - The company's net profit for the period was HKD 1.17 billion [1] - Excluding the impact of centralized procurement and exchange rates, the company's revenue grew approximately 13% year-on-year [1] Group 2: Research and Development - The company invested a total of HKD 1.02 billion in research and project development during the period, achieving 38 significant milestone advancements [1] - The company currently has 42 innovative projects in its pipeline [1] Group 3: Product Performance - The nuclear medicine segment achieved a remarkable 106% year-on-year revenue increase, generating HKD 420 million [1] - The core product, Yttrium-90 microsphere injection, continues to demonstrate strong market potential with rapid growth [1] Group 4: Strategic Developments - The company’s global leading nuclear medicine R&D and production base in Chengdu has commenced operations, facilitating a strategic leap from R&D to industrial-scale production [2] - The innovative radioactive nuclide conjugated drug GPN02006 has made breakthrough progress in domestic IIT clinical research and has been approved for oral presentation at the 2025 SNMMI annual meeting [2] Group 5: Commercialization and Market Expansion - The innovative eye drug GPN01768 (TP-03) generated over USD 100 million in overseas revenue during the first half of the year, marking a nearly 152% year-on-year increase [2] - The company is advancing the global clinical development of its self-developed innovative product STC3141, which has received approval for seven clinical batches in five countries [2]
远大医药：上半年实现营收61.1亿港元 核药板块收入同比增长106%